The tools to reduce tick-borne disease exist in various stages of development — vaccines, biocontrol agents, gene drives, next-generation diagnostics — but none of them are deployed at population scale. The United States has no approved human Lyme disease vaccine, no publicly funded tick control infrastructure, no rapid point-of-care Lyme test, and no gene drive program for any tick species. The annual aggregate cost of diagnosed Lyme disease alone is $345-968 million Emerging Infectious Diseases (CDC), 2022, and the global economic impact of ticks and tick-borne diseases reaches $22-30 billion per year MDPI (Veterinary Sciences), 2025. This article examines what is in the pipeline, what is failing, and why.

Vaccines: a twenty-year gap and a slow recovery

LYMErix: a vaccine that existed and was pulled

The withdrawal of the human Lyme disease vaccine (LYMErix) in 2002 brought the control of Lyme disease back entirely to managing tick bites and methods to suppress the local tick population Connecticut Agricultural Experiment Station / CDC, 2007. Nearly two decades later, only one candidate (VLA15, developed by Valneva) has progressed to Phase 2 clinical trials Journal of Medical Entomology / PMC, 2021. The timeline from vaccine withdrawal to a replacement candidate reaching even Phase 2 illustrates the failure of market incentives for tick-borne disease products.

Anti-tick vaccines: targeting the tick, not the pathogen

A fundamentally different vaccine approach targets tick proteins essential for feeding rather than specific pathogens. Anti-tick vaccines that block tick cement proteins or saliva components could potentially prevent transmission of multiple pathogens simultaneously — unlike pathogen-specific vaccines, which must be developed separately for each disease MDPI (Vaccines), 2024.

Gavac is the only commercially available anti-tick vaccine, targeting the Bm86 protein of Rhipicephalus microplus (cattle tick). It has been successfully implemented in livestock, but challenges remain for adaptation to other tick species and human use MDPI (Vaccines), 2024.

"Ticks notably surpass all other arthropods in their capability to transmit a diverse array of infectious agents, including viruses, bacteria, and parasites." MDPI (Vaccines), 2024

A lipid nanoparticle-encapsulated modified mRNA vaccine carrying Powassan virus prM and E genes was protective in mice against both lineage 1 and 2 Powassan virus strains and induced cross-neutralizing antibodies against other tick-borne flaviviruses MDPI (Vaccines), 2024 — suggesting that mRNA vaccine technology may accelerate development timelines.

TBE vaccines: available but underused

Tick-borne encephalitis (TBE) vaccines are widely available in Europe but underused despite more than 10,000 TBE cases reported annually in Europe and Asia MDPI (Vaccines), 2024. The Far Eastern subtype of TBEV has a case fatality rate of up to 30%, compared to approximately 2% for the European subtype MDPI (Vaccines), 2024. No vaccine exists for Powassan virus, the closely related North American flavivirus transmitted by I. scapularis MDPI (Vaccines), 2024.

Biocontrol: fungi, predators, and reservoir-targeted approaches

Entomopathogenic fungi

Metarhizium anisopliae (Metarhizium fungus) and Beauveria bassiana (Beauveria fungus) are biological control agents that infect and kill ticks. They are commercially available (Met52 is the primary product) but adoption by the pest control industry remains low — 80% of surveyed pest control companies in the NJ/NY/PA area were unfamiliar with entomopathogenic fungal products Journal of Medical Entomology / PMC, 2021.

Integrated pest management stands out as the most promising long-term solution, combining chemical, biological, physical, and vaccine approaches MDPI (Veterinary Sciences), 2025:

"The economic impact of ticks and TBDs globally is estimated to reach as much as USD 22–30 billion/annum with the largest share attributed to livestock mortality and morbidity, especially in cattle and small ruminants." MDPI (Veterinary Sciences), 2025

Emerging innovations including nanotechnology-enhanced acaricides and microbiota-targeted techniques offer new avenues beyond current methods MDPI (Veterinary Sciences), 2025, but these remain in research phases.

Reservoir-targeted vaccination: Mice Against Ticks

The most novel biocontrol approach in the vault is the "Mice Against Ticks" project — a community-guided effort to use CRISPR genome editing to heritably immunize white-footed mice (Peromyscus leucopus) against Lyme disease on Nantucket and Martha's Vineyard Philosophical Transactions of the Royal Society B, 2019.

"Mice Against Ticks is a community-guided ecological engineering project that aims to prevent tick-borne disease by using CRISPR-based genome editing to heritably immunize the white-footed mice responsible for infecting many ticks in eastern North America." Philosophical Transactions of the Royal Society B, 2019

Critically, the project explicitly does NOT use gene drive. Engineered mice would be released in spring when the natural population is low, without self-spreading genetic elements. Island populations of white-footed mice can be lastingly immunized without gene drive because geographic isolation prevents gene flow from mainland mice Philosophical Transactions of the Royal Society B, 2019.

The project is notable for its community engagement model: community members identified potential ecological consequences that the research team had not anticipated, and public concerns shaped research decisions including using only white-footed mouse DNA where possible Philosophical Transactions of the Royal Society B, 2019.

Gene drives: from mosquitoes to ticks

Gene drives are selfish genetic elements transmitted at super-Mendelian (greater than 50%) frequencies — CRISPR-Cas9-based systems can bias inheritance to up to approximately 99% in optimized systems Nature Reviews Genetics, 2022:

"Gene drives are selfish genetic elements that are transmitted to progeny at super-Mendelian (>50%) frequencies." Nature Reviews Genetics, 2022

"Recently developed CRISPR–Cas9-based gene-drive systems are highly efficient in laboratory settings, offering the potential to reduce the prevalence of vector-borne diseases, crop pests and non-native invasive species." Nature Reviews Genetics, 2022

The technology is most advanced in Anopheles mosquitoes for malaria control, with both population suppression drives (targeting female fertility) and population modification drives (rendering mosquitoes pathogen-refractory) showing high efficiency in laboratory cage trials Nature Reviews Genetics, 2022.

The first CRISPR editing of a tick: 2022

Tick gene drive research reached its first milestone in 2022, when the Gulia-Nuss lab demonstrated the first successful CRISPR-Cas9 genome editing in any tick species — and the first successful embryo injection protocol for any chelicerate (the arthropod subphylum that includes ticks, mites, spiders, and scorpions) iScience / Cell Press, 2022.

"Herein, we report a successful embryo injection protocol for the black-legged tick, Ixodes scapularis, and the use of this protocol for genome editing with CRISPR-Cas9." iScience / Cell Press, 2022

The key technical breakthrough was ablating the Gene's organ — a specialized wax gland — prior to oviposition, preventing wax coating on eggs and allowing needle penetration. Tick embryos were previously considered uninjectable iScience / Cell Press, 2022. Editing efficiency was low but real: 1.8% for Proboscipedia via embryo injection, 66.6% for chitinase, and 1.7-4.2% for ReMOT Control (adult injection) iScience / Cell Press, 2022.

The prior state of tick genetics was summarized by the same lab: RNAi — the only functional genomics tool previously available for ticks — had significant limitations including incomplete silencing, transient knockdown, and inapplicability to embryos and larvae Frontiers in Cellular and Infection Microbiology, 2021. The 2022 breakthrough removed the most fundamental barrier to tick genetic manipulation.

Containment and resistance: can a gene drive be stopped?

Two major safety concerns attend any gene drive deployment: resistance alleles (target site mutations that prevent Cas9 cutting, potentially rendering a gene drive ineffective over time) and ecological irreversibility Nature Reviews Genetics, 2022.

Containment strategies include split-drive systems (where Cas9 and guide RNA are on separate chromosomes, preventing indefinite spread), daisy-chain drives (geographically limited), and genetic neutralizing elements Nature Reviews Genetics, 2022, International Risk Governance Center (IRGC) / EPFL, 2023.

Experimental evidence for one containment strategy emerged in 2024, when researchers demonstrated that an anti-CRISPR protein (AcrIIA4) could effectively prevent gene drive spread in Anopheles gambiae mosquitoes. The anti-drive showed 100% inhibition of gene drive homing, reducing super-Mendelian inheritance (96-99%) back to Mendelian levels (52-55%) Nature Communications, 2024.

"The anti-drive strain was able to prevent the spread and to induce the decline and even elimination, in one case, of the suppressive Ag(QFS)1 gene drive in age-structured overlapping populations." Nature Communications, 2024

The regulatory landscape has no clear pathway

"Theoretically, the release of just a few organisms could change populations in ecosystems permanently." International Risk Governance Center (IRGC) / EPFL, 2023

"GDOs present characteristics of emerging risks that are accompanied by significant complexity, uncertainty and ambiguity." International Risk Governance Center (IRGC) / EPFL, 2023

The US regulatory landscape involves jurisdictional overlap among EPA (pesticide regulation if the drive suppresses a pest), USDA (if it involves a plant pest or animal), and FDA (if it involves a modified animal) — with no clear single pathway for gene drive regulation International Risk Governance Center (IRGC) / EPFL, 2023. Internationally, governance centers on the Convention on Biological Diversity and the Cartagena Protocol on Biosafety, but there is no binding international agreement specifically addressing gene drives International Risk Governance Center (IRGC) / EPFL, 2023.

Social, cultural, and economic risk pathways include impacts on indigenous communities, food sovereignty, and the ethical questions of permanently modifying wild populations without consent of affected communities International Risk Governance Center (IRGC) / EPFL, 2023.

Diagnostics: the search for a better test

Current testing misses early infections

The modified two-tier testing (MTTT) for Lyme disease — using two enzyme immunoassays run concurrently instead of the traditional EIA followed by Western blot — was recently FDA-cleared and improves sensitivity for early infections while being less subjective, less labor-intensive, and faster than standard two-tier testing American Society for Microbiology, 2019. However, both approaches rely on the host antibody response, which may not be detectable in early disease — the 2020 IDSA/AAN/ACR guidelines recommend that erythema migrans be diagnosed clinically without laboratory testing because serologic testing may be negative in early disease IDSA / AAN / ACR, 2020.

Next-generation approaches

Metabolomic testing for Lyme disease, still in the research phase, has shown 88% sensitivity and 95% specificity — a fundamentally different approach that detects host metabolic changes rather than antibodies American Society for Microbiology, 2019. This approach could potentially detect infection before the antibody response develops, addressing the critical window where current tests fail.

The HHS National Inventory identified diagnostic technologies as "badly needed" but noted there is "no clear path to bring them to market, and little has been done to remove existing barriers" U.S. Department of Health and Human Services, 2022.

Disulfiram: straddling treatment and diagnostics research

Disulfiram's investigation as a Lyme disease treatment (covered in detail in After Infection) also represents a diagnostics-adjacent development — the drug was identified through a high-throughput screen of over 4,000 FDA-approved compounds for activity against stationary-phase B. burgdorferi MDPI (Antibiotics), 2020. The 36.4% enduring remission rate in the retrospective series MDPI (Antibiotics), 2020 and the tolerability problems identified in the Columbia pilot Frontiers in Medicine, 2025 together define the current state of the most-discussed experimental treatment.

The policy failure

For the full argument on why tick control remains an individual responsibility while mosquito control is publicly funded, see 8.5-tick-control-infrastructure-gap-vs-mosquito.

The core facts bear repeating here: several thousand people in the United States work full-time on mosquito control, while only a few dozen work on public-health tick control Emerging Infectious Diseases (CDC), 2020. Tick-borne diseases represent more than 75% of all reported vector-borne infections in the country U.S. Department of Health and Human Services, 2022, and an estimated 476,000 new cases of Lyme disease are diagnosed each year U.S. Department of Health and Human Services, 2022.

The market failure

The private sector has little incentive to invest. The Tick-Borne Disease Working Group identified the structural problem:

"Several subcommittees cited increased government intervention in the development of diagnostics and treatment protocols as detrimental to transforming the tick-borne disease landscape. The subcommittee members believed that progress has been impeded by a heavy regulatory burden and low likelihood of profitability, which discourage the private-sector investments needed to catalyze the entry of new products into the market." U.S. Department of Health and Human Services, 2022

Nootkatone, a tick-killing compound derived from Alaskan yellow cedar, took nearly 15 years from initial proof-of-concept to near product registration Journal of Medical Entomology / PMC, 2021. The combined national response, despite significant investment, remains inadequate:

"Despite significant investment at all levels to respond to tick-borne diseases and associated illnesses, the combined response remains inadequate." U.S. Department of Health and Human Services, 2022

The funding gap

The Working Group recommended that BARDA and the newly established ARPA-H develop tick-borne disease portfolios to accelerate the pipeline U.S. Department of Health and Human Services, 2022. Federal funding for tick-borne disease activities increased from 2018 to 2021, including the NIH Strategic Plan for Tickborne Disease Research and the LymeX Innovation Accelerator public-private partnership U.S. Department of Health and Human Services, 2022. But the National Inventory found that treatment research remained underrepresented in published literature — diagnosis and surveillance dominate, while pathogenesis, clinical presentation, and disease treatment receive less attention U.S. Department of Health and Human Services, 2022.

The economic calculus is stark. US annual Lyme disease treatment costs of $345-968 million Emerging Infectious Diseases (CDC), 2022 dwarf any plausible investment in prevention, vaccines, or diagnostics. The costs of inaction are borne by individual patients: 41.3% of chronic Lyme patients stopped working, 43.2% spent more than $5,000 out of pocket PeerJ, 2014, and 74% of the clinicians who treat them do not participate in insurance networks MDPI (Healthcare), 2022.

"The negative societal effects of ticks and tickborne diseases in the United States, including a general feeling that family members are not safe during outdoor activities in the backyard and elsewhere, has reached the point where we need to rethink the basic concepts of how to counter this threat." Emerging Infectious Diseases (CDC), 2020

Sources

Compiler Notes

  • The policy failure section deliberately defers to 8.5-tick-control-infrastructure-gap-vs-mosquito per compilation instructions. Only the core framing facts are restated; the full evidence is in the existing article.
  • VLA15 pipeline status: the vault sources reference Phase 2 trials (Eisen 2021). More recent Phase 3 data may exist but is not in the vault. Claim not in index — possible source gap for VLA15 Phase 3 status.
  • The gene drive section covers mosquito applications as context for future tick applications. No tick gene drive has been proposed or tested — the 2022 Gulia-Nuss paper demonstrates only basic genome editing capability, not a drive system. This distinction is maintained throughout.
  • The diagnostics section is thinner than others — the vault has the ASM 2019 review mentioning metabolomics (88% sensitivity, 95% specificity) but lacks a dedicated next-generation Lyme diagnostics review. The lyme-diagnostics-failure-next-generation node would benefit from a focused source.
  • The biocontrol section covers entomopathogenic fungi and reservoir-targeted vaccination but lacks coverage of natural predators (guinea fowl, opossums) from the vault's analytical sources. The Stafford handbook mentions guinea fowl in passing but no dedicated study exists in the vault.
  • Disulfiram is placed at the intersection of treatment and diagnostics research as the compilation instructions list it under both the After Infection and Systemic Picture articles. The full clinical data is in After Infection; this article provides the pipeline/research context.